Summary by Futu AI
HUTCHMED (China) Limited ("HUTCHMED") will hold offline and online meetings on July 9, 2024 in Shanghai to share its latest research and development progress. The meeting will be hosted by senior management, introducing the company's R&D strategy and vision, and highlighting the clinical research progress of candidate drugs including surufatinib, savolitinib and HMPL-306. The offline meeting will be held from 3 p.m. to 5 p.m. Hong Kong time and offer live streaming in Chinese (Mandarin). The English webcast will start at 8:30 p.m. on the same day and is expected to last for 2 hours. Investors can visit the company's website before the meeting to download the necessary software to listen to the webcast, and can also listen to the replay on the website within 90 days after the meeting. HUTCHMED is a biomedical company focused on the development of cancer and immunological disease treatments, with three drugs already on the market in China, one of which is also approved in the United States.